Atherosclerosis progression in the APPLE trial can be predicted in young people with juvenile-onset systemic lupus erythematosus using a novel lipid metabolomic signature.
Junjie PengPierre DönnesStacy P ArdoinLaura Eve SchanbergLaura B Lewandowskinull nullGeorge A RobinsonElizabeth C JuryCoziana CiurtinPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Significant baseline heterogeneity and distinct subclinical atherosclerosis progression trajectories exist in JSLE. Metabolomic signatures can predict atherosclerosis progression in some JSLE patients with relevance for clinical trial stratification.